2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P991206
    Human IgG2 lambda, Isotype Control 98%
    Human IgG2 lambda, Isotype Control, a human monoclonal antibody, is an isotype control for human IgG2λ antibody.
    Human IgG2 lambda, Isotype Control
  • HY-P991207
    Human IgG1 (L234A/L235A) kappa, Isotype Control 98%
    Human IgG1 (L234AL235A) kappa, Isotype Control, a human monoclonal antibody, is an isotype control for human IgG1κantibody.
    Human IgG1 (L234A/L235A) kappa, Isotype Control
  • HY-P991208
    Flt-3L-Ig (hum/hum) 98%
    Flt-3L-Ig (hum/hum) (hFlt3L) is a Flt3 activator. Flt-3L-Ig (hum/hum) enhances OKT3-induced inflammatory cytokine release from myeloid and dendritic cells in BRGSF-CBC mice, as well as the number and distribution of human immune cells, exhibiting cytokine release syndrome (CRS).
    Flt-3L-Ig (hum/hum)
  • HY-P991218
    Anti-IL11 Antibody (X203) 98%
    Anti-IL11 Antibody (X203) is a human-derived IgG1, κ type antibody inhibitor, targeting to human IL-11. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-IL11 Antibody (X203)
  • HY-P991224
    CAP-100 98%
    CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL.
    CAP-100
  • HY-P991225
    BI-1206 98%
    BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL).
    BI-1206
  • HY-P991251
    QX006N 98%
    QX006N is a humanized monoclonal antibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases.
    QX006N
  • HY-P991252
    XmAb-7195
    XmAb-7195 (AIMab-7195) is a human monoclonal antibody (mAb) targeting IGHE. XmAb-7195 can be used in Food hypersensitivity, Allergic asthma, Allergic rhinitis, Atopic dermatitis and Conjunctivitis research.
    XmAb-7195
  • HY-P991255
    VRDN-002
    VRDN-002 is a human monoclonal antibody (mAb) targeting IGF1R/CD221. VRDN-002 reduces inflammation and proptosis in thyroid eye disease (TED). VPI-2690B can be used in Graves ophthalmopathy research.
    VRDN-002
  • HY-P991256
    FB-825
    FB-825 is a human monoclonal antibody (mAb) targeting IGHE. FB-825 targets the CεmX domain of membrane IgE (mIgE), resulting in the downregulation of mIgE-positive B cells and the production of IgE. FB-825 can be used in Allergic asthma, Atopic dermatitis, Job syndrome and Allergic rhinitis research.
    FB-825
  • HY-P991258
    CNTO-5825 98%
    CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis.
    CNTO-5825
  • HY-P991259
    MEDI-7836 98%
    MEDI-7836 is a humanized monoclonal antibody inhibitor that targets the interleukin-13 receptor. MEDI-7836 is promising for research of inflammation-related diseases.
    MEDI-7836
  • HY-P991261
    CJM-112 98%
    CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways.
    CJM-112
  • HY-P991262
    QX-002N 98%
    QX-002N is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). QX-002N is promising for research of inflammatory diseases.
    QX-002N
  • HY-P991263
    SCH-900117 98%
    SCH-900117 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis.
    SCH-900117
  • HY-P991264
    ZL-1102 98%
    ZL-1102 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). ZL-1102 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis.
    ZL-1102
  • HY-P991266
    SM-17 98%
    SM-17 is a humanized monoclonal antibody inhibitor targeting interleukin 25 (IL-25) and interleukin-17 receptor B (IL17RB). SM-17 is promising for research of immune system diseases.
    SM-17
  • HY-P991268
    DLX2323 98%
    DLX2323 is an interleukin-1β (IL-1β) modulator. DLX2323 is promising for research of inflammatory diseases.
    DLX2323
  • HY-P991270
    MT204 98%
    MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy.
    MT204
  • HY-P991271
    NN-8828 98%
    NN-8828 (NNC-114-0005) is a humanized monoclonal antibody inhibitor targeting interleukin-21 (IL-21). NN-8828 is promising for research of immune system diseases.
    NN-8828
Cat. No. Product Name / Synonyms Application Reactivity